HK1016482A1 - Tumor rejection antigens presented by hla-b44 molecules, and uses thereof. - Google Patents

Tumor rejection antigens presented by hla-b44 molecules, and uses thereof.

Info

Publication number
HK1016482A1
HK1016482A1 HK99101529A HK99101529A HK1016482A1 HK 1016482 A1 HK1016482 A1 HK 1016482A1 HK 99101529 A HK99101529 A HK 99101529A HK 99101529 A HK99101529 A HK 99101529A HK 1016482 A1 HK1016482 A1 HK 1016482A1
Authority
HK
Hong Kong
Prior art keywords
hla
tumor rejection
molecules
rejection antigens
antigens presented
Prior art date
Application number
HK99101529A
Other languages
English (en)
Inventor
Jean Herman
Pierre Coulie
Pierre Van Der Bruggen
Thierry Boon-Falleur
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of HK1016482A1 publication Critical patent/HK1016482A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
HK99101529A 1995-09-21 1999-04-13 Tumor rejection antigens presented by hla-b44 molecules, and uses thereof. HK1016482A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/531,864 US5977300A (en) 1994-06-03 1995-09-21 Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof
PCT/US1996/015078 WO1997010837A1 (en) 1995-09-21 1996-09-19 Tumor rejection antigens presented by hla-b44 molecules, and uses thereof

Publications (1)

Publication Number Publication Date
HK1016482A1 true HK1016482A1 (en) 1999-11-05

Family

ID=24119368

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99101529A HK1016482A1 (en) 1995-09-21 1999-04-13 Tumor rejection antigens presented by hla-b44 molecules, and uses thereof.

Country Status (15)

Country Link
US (2) US5977300A (zh)
EP (1) EP0854727B1 (zh)
JP (1) JP3355360B2 (zh)
CN (1) CN1119169C (zh)
AT (1) ATE209041T1 (zh)
AU (1) AU714884B2 (zh)
CA (1) CA2232325C (zh)
DE (1) DE69617255T2 (zh)
DK (1) DK0854727T3 (zh)
ES (1) ES2168514T3 (zh)
HK (1) HK1016482A1 (zh)
NZ (1) NZ320837A (zh)
PT (1) PT854727E (zh)
TW (1) TW387899B (zh)
WO (1) WO1997010837A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060257A (en) * 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
US20020164654A1 (en) * 2000-01-20 2002-11-07 Rosalie Luiten MAGE antigenic peptides which bind HLA-B35 and HLA-B44
US11945850B2 (en) * 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888512A (en) * 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
WO1994005304A1 (en) * 1992-08-31 1994-03-17 Ludwig Institute For Cancer Research Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof
US6060257A (en) * 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
US5997870A (en) * 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules

Also Published As

Publication number Publication date
CN1119169C (zh) 2003-08-27
EP0854727B1 (en) 2001-11-21
CA2232325A1 (en) 1997-03-27
EP0854727A1 (en) 1998-07-29
DE69617255D1 (de) 2002-01-03
CA2232325C (en) 2007-01-09
DE69617255T2 (de) 2002-07-18
ES2168514T3 (es) 2002-06-16
ATE209041T1 (de) 2001-12-15
DK0854727T3 (da) 2002-02-25
PT854727E (pt) 2002-05-31
AU7365996A (en) 1997-04-09
US6171806B1 (en) 2001-01-09
NZ320837A (en) 1999-02-25
JPH11509860A (ja) 1999-08-31
AU714884B2 (en) 2000-01-13
JP3355360B2 (ja) 2002-12-09
TW387899B (en) 2000-04-21
WO1997010837A1 (en) 1997-03-27
US5977300A (en) 1999-11-02
EP0854727A4 (en) 1999-08-18
CN1197393A (zh) 1998-10-28

Similar Documents

Publication Publication Date Title
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
AP9801392A0 (en) Concentrated antibody preparation.
EP0658113A4 (en) ISOLATED NONAPEPTIDE DERIVED FROM THE MAGE-3 GENE AND PRESENTED BY HLA-A1, AND USES THEREOF.
AU6632496A (en) Cell derived antigen presenting vesicles
ATE267254T1 (de) Isolierte peptide, die mit mhc mulekül hla-c-klon 10 komplexe bilden und ihre verwendungen
EP2022800A3 (en) Compositions for the therapy and diagnosis of ovarian cancer
ATE209680T1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
TR199801722T2 (xx) Peptit imm�nojenler.
BR9809656A (pt) Composição imunopotencializante
WO1998039034A3 (de) Verwendung von anti-cd44 antikörper enthaltenden präparationen zur behandlung bestimmter tumore und zur unterdrückung von immunreaktionen
AU2709295A (en) Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
GB2355983A (en) Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class 1 molecule and an attaching means
HK1031994A1 (en) Methods for detection and treatment of individuals having abnormal cells expressing hla-a2/tyrosinase peptide antigens
ZA971403B (en) Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof.
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
AU6921300A (en) Novel glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
CA2184175A1 (en) Isolated, tyrosinase derived peptides and uses thereof
IL187595A0 (en) Antitumor antibodies, proteins, and uses thereof
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
HK1016482A1 (en) Tumor rejection antigens presented by hla-b44 molecules, and uses thereof.
AU1991097A (en) Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
WO2001029220A3 (en) Mage-a12 antigenic peptides and uses thereof
UA42741C2 (uk) Пептид маститної вакцини (варіанти), пептид складного антигенного представлення (варіанти), фармацевтична композиція (варіанти)
AU653332B2 (en) Synthetic peptides which contain sequences from factor VIIa, and the use thereof

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF INVENTOR

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080919